Solventum (NYSE:SOLV) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Solventum (NYSE:SOLV) released its earnings results on Thursday. The company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.11, FiscalAI reports. The business had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.93 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period last year, the company earned $1.50 earnings per share.

Here are the key takeaways from Solventum’s conference call:

• Q3 sales were $1.95 billion, down 7% reported and 2.8% organically, including a 630-basis-point headwind from the planned reversal of ERP-related advance orders. Management said normalized organic growth was about 4%; EPS was $1.45, including an estimated $0.35 impact from the timing reversal.
• Solventum raised its 2026 outlook, now expecting organic sales growth toward the high end of its 2.5%–3% range and EPS of $7.20–$7.30, up from $7.10–$7.20. Operating margin is expected toward the high end of its 22.2%–22.7% range.
• The company completed its largest ERP cutover and said its separation from 3M is more than 90% complete, with the remaining transition services expected to end by the close of 2027. A renegotiated supply agreement also removes a previously anticipated 100-basis-point gross-margin headwind beginning in 2027; management expects separation costs to step down, supporting free cash flow.
• Solventum is evaluating a sale or spin-off of Health Information Systems (HIS), with timing and structure still undecided. Management estimates the separation would cause about 400 basis points of annualized net operating margin dilution, though it expects to use proceeds first to pay down debt and then return most remaining proceeds to shareholders.
• Management highlighted growth opportunities from underpenetrated products, new launches, and acquisitions, including V.A.C. wound therapy and Acera. Acera grew 35% and had its best quarter on record, while the company said its combined-use clearance for Restrata and V.A.C. enables joint marketing.

Solventum Stock Up 3.6%

Solventum stock traded up $3.17 during midday trading on Friday, hitting $90.34. 3,168,921 shares of the company’s stock were exchanged, compared to its average volume of 1,109,088. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. Solventum has a 12 month low of $62.38 and a 12 month high of $94.16. The firm has a 50-day moving average of $87.73 and a two-hundred day moving average of $78.70. The company has a market cap of $15.38 billion, a PE ratio of 101.51, a P/E/G ratio of 1.24 and a beta of 0.69.

Key Headlines Impacting Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Solventum earned $1.45 per share on $1.95 billion in revenue, beating consensus estimates of $1.34–$1.35 per share and $1.93 billion in sales. The company raised its 2026 adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 results
• Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an overweight rating; Wells Fargo increased its target to $95 while retaining an equal-weight rating. Jefferies raised its target to $98. Piper Sandler rating
• Neutral Sentiment: The company said the 7% year-over-year sales decline (organic sales down 2.8%) reflected, in part, a temporary ERP transition effect: customers had placed advance orders in the prior quarter ahead of the system cutover. Solventum also reported that its separation process was more than 90% complete. Q3 earnings and ERP impact
• Negative Sentiment: Despite the quarterly beat, revenue fell 7% year over year and EPS was down from $1.50 a year ago, highlighting ongoing comparisons and execution risks. Quarterly earnings details

Analysts Set New Price Targets

Several research analysts recently commented on SOLV shares. Benchmark reaffirmed a “buy” rating on shares of Solventum in a research note on Thursday, October 8th. Jefferies Financial Group reissued a “buy” rating on shares of Solventum in a research report on Thursday, October 8th. Piper Sandler restated an “overweight” rating and issued a $110.00 target price (up from $105.00) on shares of Solventum in a research note on Friday. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Stifel Nicolaus raised their target price on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $90.27.

Solventum Company Profile

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.